News Channels

20 Apr 2022 BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
20 Apr 2022 Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
19 Apr 2022 Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
19 Apr 2022 Amgen announces positive top-line results from phase 3 study of ABP 654, biosimilar candidate to Stelara (ustekinumab)
19 Apr 2022 Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
18 Apr 2022 Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
15 Apr 2022 China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
15 Apr 2022 Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
15 Apr 2022 Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
14 Apr 2022 INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease
14 Apr 2022 Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)
14 Apr 2022 Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
14 Apr 2022 Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
14 Apr 2022 European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
14 Apr 2022 Ubix Therapeutics, SK Biopharmaceuticals enter into research collaboration agreement to develop novel therapeutics based on targeted protein degradation
14 Apr 2022 AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
14 Apr 2022 CDR-Life Announces $76 Million Raised in Series A Funding
13 Apr 2022 Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
13 Apr 2022 Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
13 Apr 2022 Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up